The Role of Advanced Glycation End Products in Saphenous Vein Graft Failure.

<bold><italic>Objective:</italic></bold> We aimed to investigate the relationship between advanced glycation end product (AGE) levels in patients with saphenous vein graft (SVG) failure and in patients without SVG failure. <bold><italic>Subjects and Methods:</italic></bold> In our study, 55 patients with a history of previous coronary artery bypass grafting (CABG) surgery, who subsequently underwent coronary angiography for any reason and were found to have either SVG occlusion or significant lesions, were included as study patients. Additionally, 55 patients who have had CABG surgery without SVG failure for at least 1 year served as the control group. AGE values of the patients were measured using the skin autofluorescence method. <bold><italic>Results:</italic></bold> In our study results, we observed a significant difference in AGE levels between the two groups of patients with similar demographic characteristics (SVG failure groups AGE 3.2 [2.8–3.6] vs. control groups AGE 2.4 [2.1–2.7] <italic>p</italic> < 0.001). In the receiver operating characteristic curve analysis, we determined the ability of AGE levels to detect SVG failure with an area under the curve of 0.869. We found that in patients with AGE >3, it could detect SVG failure with a sensitivity of 70.9% and a specificity of 87.3%. <bold><italic>Conclusions:</italic></bold> Our results demonstrate that AGE levels can predict SVG failure risk inexpensively, easily, and quickly. [ABSTRACT FROM AUTHOR]